Mark Hillman

Net selling

Hillman Capital Management, Inc. — managed by Mark Hillman; US equity positions disclosed quarterly via SEC 13F

Data as of 2026-06-30 (filed 2026-08-14) · Source: SEC EDGAR

Portfolio value$138.2M (−4%)

Holdings54 (−2)

Top holdingCvs Health Corp

Below band3

New

Added

Exited

By what price implies: 23 demand a demanding growth rate, 6 modest.

13F × valuation

Valuation posture

Of 17 valued US positions, 3 trade below a conservative value band (as of 2026-10-19):

Adobe IncADBE29% · below
Fiserv IncFISV26% · below
Bristol-Myers Squibb CoBMY15% · below

SEC 13F · latest filing

Holdings

Security	Value	Valuation	Holders	Shares	Weight	Signal
Cvs Health CorpCVS	$5.7M	—	13	55,475	4.2%	Core · 8 quarters
Biogen IncBIIB	$5.2M	—	3	23,993	3.8%	Core · 8 quarters
Dupont De Nemours IncDD	$5.1M	—	3	37,745	3.7%	Big new position
Warner Bros Discovery IncWBD	$5.1M	—	6	189,986	3.7%	Core · 8 quarters
Baxter Intl IncBAX	$5.0M	—	7	236,032	3.6%	Core · 8 quarters
International Flavors&FragraIFF	$5.0M	—	5	62,875	3.6%	—
Gsk PlcGSK	$4.8M	—	8	92,383	3.5%	—
Carmax IncKMX	$4.8M	—	5	91,385	3.5%	—
Boeing CoBA	$4.7M	—	8	21,574	3.4%	—
Zimmer Biomet Holdings IncZBH	$4.6M	—	7	53,943	3.4%	—
Kraft Heinz CoKHC	$4.6M	—	10	196,494	3.4%	—
Brown Forman CorpBF.B	$4.6M	—	7	172,514	3.3%	—
Pfizer IncPFE	$4.2M	—	11	174,610	3.0%	—
Lauder Estee Cos IncEL	$4.0M	—	5	50,226	2.9%	—
Fiserv IncFISV	$3.8M	Below value	9	78,456	2.8%	—
Microsoft CorpMSFT	$3.8M	—	42	10,296	2.8%	—
The Campbells CompanyCPB	$3.6M	—	3	161,043	2.6%	—
Adobe IncADBE	$3.5M	Below value	12	17,288	2.6%	—
Ishares TrEFA	$3.3M	—	4	31,743	2.4%	Adding · 5 quarters
Nike IncNKE	$3.2M	—	5	78,213	2.3%	—
Taiwan Semiconductor ManufacTSM	$2.7M	—	28	5,608	1.9%	—
Bristol-Myers Squibb CoBMY	$2.6M	Below value	9	45,235	1.9%	—
West Pharmaceutical Svsc IncWST	$2.6M	—	4	7,106	1.8%	—
Us BancorpUSB	$2.5M	—	8	41,252	1.8%	—
Veeva Sys IncVEEV	$2.5M	—	7	14,008	1.8%	—

Cvs Health CorpCVSCore · 8 quarters
Value$5.7MValuation—Holders13Weight4.2%
Biogen IncBIIBCore · 8 quarters
Value$5.2MValuation—Holders3Weight3.8%
Dupont De Nemours IncDDBig new position
Value$5.1MValuation—Holders3Weight3.7%
Warner Bros Discovery IncWBDCore · 8 quarters
Value$5.1MValuation—Holders6Weight3.7%
Baxter Intl IncBAXCore · 8 quarters
Value$5.0MValuation—Holders7Weight3.6%
International Flavors&FragraIFF—
Value$5.0MValuation—Holders5Weight3.6%
Gsk PlcGSK—
Value$4.8MValuation—Holders8Weight3.5%
Carmax IncKMX—
Value$4.8MValuation—Holders5Weight3.5%
Boeing CoBA—
Value$4.7MValuation—Holders8Weight3.4%
Zimmer Biomet Holdings IncZBH—
Value$4.6MValuation—Holders7Weight3.4%
Kraft Heinz CoKHC—
Value$4.6MValuation—Holders10Weight3.4%
Brown Forman CorpBF.B—
Value$4.6MValuation—Holders7Weight3.3%
Pfizer IncPFE—
Value$4.2MValuation—Holders11Weight3.0%
Lauder Estee Cos IncEL—
Value$4.0MValuation—Holders5Weight2.9%
Fiserv IncFISV—
Value$3.8MValuationBelow valueHolders9Weight2.8%
Microsoft CorpMSFT—
Value$3.8MValuation—Holders42Weight2.8%
The Campbells CompanyCPB—
Value$3.6MValuation—Holders3Weight2.6%
Adobe IncADBE—
Value$3.5MValuationBelow valueHolders12Weight2.6%
Ishares TrEFAAdding · 5 quarters
Value$3.3MValuation—Holders4Weight2.4%
Nike IncNKE—
Value$3.2MValuation—Holders5Weight2.3%
Taiwan Semiconductor ManufacTSM—
Value$2.7MValuation—Holders28Weight1.9%
Bristol-Myers Squibb CoBMY—
Value$2.6MValuationBelow valueHolders9Weight1.9%
West Pharmaceutical Svsc IncWST—
Value$2.6MValuation—Holders4Weight1.8%
Us BancorpUSB—
Value$2.5MValuation—Holders8Weight1.8%
Veeva Sys IncVEEV—
Value$2.5MValuation—Holders7Weight1.8%

Showing top 25 of 54 positions

Exited this quarter (5)Dupont De Nemours Inc、Ge Aerospace、Spdr Series Trust、Ishares Tr、Spdr Series Trust

What is a superinvestor

About this investor

Portfolio overview

Hillman Capital Management, Inc.'s most recent 13F filing, for the quarter ended 2026-06-30, reports 54 positions worth $138.2M. The top 5 holdings represent 19% of that value, a broadly diversified portfolio.

The single largest position is Cvs Health Corp at 4.2% of the portfolio, followed by Biogen Inc at 3.8% and Dupont De Nemours Inc at 3.7%.

Against the prior quarter, Mark Hillman opened 3 new positions, exited 5, added to 14, and trimmed 35. The largest new buy was Dupont De Nemours Inc. The most notable sale was the full exit from Dupont De Nemours Inc.

Across all 8 quarters on file, Cvs Health Corp has appeared in every filing, as has Biogen Inc. Cvs Health Corp currently ranks first by value.

A 13F is filed roughly 45 days after quarter-end and covers only long positions in US-listed equities, so it is a lagging and partial view of the portfolio. Source: SEC EDGAR.

Mark Hillman has no positions in the strike zone right now. Browse the whole market by value band

Sources· SEC EDGAR 13F as of 2026-06-30 · filed 2026-08-14

Stay Updated

New-quarter 13F moves and valuation updates, to your inbox.